• Products
    Investment Suite
    Stocks
    Mutual Funds
    Future and Options
    IPO
    Exchange Traded Funds
    Commodity
    Stockcase (Stock Baskets)
    Currency
    Non Convertible Debentures
    Sovereign Gold Bond
    Exclusive
    NRI Account
    Corporate/HUF Trading Account
    Private Client Group
    Features
    SipIt
    MTF
    Investment Suite
    Exclusive
    Features
  • Platform
    Trading Platforms
    Kotak Neo App & Web
    Nest Trading Terminal
    NEO Trade APIs
    Features and Tools
    MTF
    Securities Accepted as Collateral
    Margin Requirements
    Equity Screeners
    Payoff Analyzer
    Calculators
    SIP Calculator
    Lumpsum Calculator
    Brokerage Calculator
    Margin Calculator
    MTF Calculator
    SWP Calculator
    CAGR Calculator
    Simple Interest Calculator
    ELSS Calculator
    Step up SIP Calculator
    All Calculators
    Trading Platforms
    Features and Tools
    Calculators
  • Pricing
  • Research
    Research Calls
    Long Term calls
    Short Term calls
    Intraday calls
    Derivatives calls
    Pick of the week
    Top Monthly Picks
    Research Reports
    Fundamental Research Report
    Technical Research Report
    Derivative Research Report
    Research Calls
    Research Reports
  • Market
    Market Movers
    Share Market Today
    Top Gainers
    Top Losers
    Stocks
    Large Cap
    Mid Cap
    Small Cap
    Indices
    Nifty 50
    Bank Nifty
    FinNifty
    Nifty Midcap India
    VIX
    All Indian Indices
    Mutual Funds
    SBI Mutual Funds
    HDFC Mutual Funds
    Axis Mutual Funds
    ICICI Prudential Mutual Funds
    Nippon India Mutual Funds
    All AMC's
    IPO
    Upcoming IPO
    Current IPO
    Closed IPO
    Recently Listed IPO
    Market Movers
    Stocks
    Indices
    Mutual Funds
    IPO
  • Learn
    Stockshaala
    Basics of Stock Market
    Introduction to Fundamental Analysis
    Introduction to Technical Analysis
    Derivatives, Risk management & Option Trading Strategies
    Personal Finance
    Resource
    Market Ready
    Kotak Insights
    Infographic
    Podcast
    Webinars
    Youtube Channel
    Quarterly Results
    Investing Guide
    Demat Account
    Trading Account
    Share Market
    Intraday Trading
    IPO
    Mutual Funds
    Events
    Budget 2025
    Muhurat Trading
    Share Market Holiday
    Market Outlook 2025
    Stockshaala
    Resource
    Investing Guide
    Events
  • Partner
    Business Associates
    Kotak Connect Plus
    Startup connect
  • Support
    FAQs
    Circulars
    Bulletins
    Contact Us
    Forms Download
    Get your Statement

-- / --

IPO Details

Issue Date

--

Investment/lot

--

Price Range

--

Lot Size

--

IPO Size

N/A

Schedule of Amanta Healthcare Ltd

Start date

End date

Allotment of bids

Refund Initiation

Listing on exchange

Initial public offering of up to 1,25,00,000 equity shares of face value of Rs. 10 each (equity shares) of the company for cash at a price of Rs. [] per equity share (including a share premium of Rs. [] per equity share) (issue price) aggregating up to Rs. [] crores (the issue) comprising of its post-issue paid-up equity share capital of the company. The face value of the equity share is Rs. 10 each and the issue price is [] times the face value of the equity shares. The price band and the minimum bid lot size will be decided by the company.

Read More

Amanta Healthcare Limited is an IPO of up to 1,25,00,000 equity shares. It consists of a fresh issue aggregating up to 1,25,00,000 equity shares. The shares will be allotted on TBA. The credit of shares to the demat account will take place on TBA and the initiation of refunds will take place on TBA.

  • Funding capital expenditure requirements for civil construction work and towards purchase of equipment, plant and machinery for setting up the new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat.
  • Funding capital expenditure requirements towards purchase of equipment, plant and machinery for setting up a new manufacturing line for Small Volume Parenteral (SVP) at Hariyala, Kheda, Gujarat.
  • General corporate purposes.
Detail Information
Upper Price Band (₹)
TBA
Existing Shares to be Sold
Not Applicable
Fresh Issue
Up to 1,25,00,000 Equity Shares
EPS (₹) For the year ended March 31, 2024
1.35
Investor Category Shares Offered
QIBs Share Offered
Not more than 50% of the Issue
Non-Institutional Investors (NIIs)
Not less than 15% of the Issue
Retail Individual Investors
Not less than 35% of the Issue

Industry Outlook

In 2021, healthcare expenditure as a percentage of GDP increased to 10.3% globally (~$ 980,000 crores), owing to prioritisation of public health during the pandemic, availability of better medical facilities, advancements in medicine and increase in disposable incomes.

For fiscal 2024, India exported formulations worth USD 1230 crores to regulated markets, with US alone contributing ~66% of the total exports (to regulated markets). India's share of formulation exports is low in value terms as India is primarily into trade generic and branded generics exports. However, India's share in formulation exports to US markets has improved over the years as it capitalised on opportunities created by patent expires. Europe is another major export destination for India with a share of ~24% (overall exports to regulated markets). India exported formulation worth USD 1010 crores to semi-regulated markets in fiscal 2024.

Indian injectables market in Indian domestic formulation industry has recorded steady growth in recent years. The market grew at a CAGR of 7.2% from ₹19,200 crores in fiscal 2019 to ₹27200 crores in fiscal 2024. Going ahead, the Indian injectables market is expected to grow at a CAGR of 7.5-8.5% over the next five fiscal years from fiscal 2024 to fiscal 2029 to reach ₹37,500-40,000 crores by fiscal 2029.

Indian IV fluids market is estimated to be valued at ~ ₹ 4500-4700 crores as of fiscal 2024, compared to ~ ₹2900 crores in fiscal 2019. Going ahead with growth of overall healthcare delivery market in India and the factors outlined above the industry is estimated to register a CAGR of ~9-11% between fiscals 2024-2029 and reach ~₹7000-8000 crores by fiscal 2029 owing to sustained demand from end-use segments like hospitals and clinics.

Company Information

Amanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic containers with Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technology.

They manufacture large volume parenterals (LVPs) and small volume parenterals (SVPs) in six therapeutic segments. In addition to that, they also manufacture medical devices. They manufacture fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in the therapeutic segment and products like irrigation, first-aid solution, eye lubricants, etc. in the medical device segment. They offer a wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume ranging from 2ml to 1000 ml.

Well established manufacturer of pharmaceutical formulations with diverse product portfolio and diverse market.

Incorporated in the year 1994, they have a well-diversified product portfolio with a product group of six therapeutic segments namely fluid therapy, formulations, diluents, ophthalmic, respiratory care, and irrigation solutions. In terms of container offerings, they offer a wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume ranging from 2ml to 1000 ml.

Large manufacturing capabilities.

The company has four LVP manufacturing lines, which include two lines of conventional single-port containers with ABFS technology and two lines of SteriPort products with ISBM technology. Their manufacturing facility is spread over 66,852.00 sq. metres of land located at village Hariyala, District Kheda, Gujarat, India.

Wide domestic and international marketing network.

They have sales, marketing and distribution capabilities in India. They have over 316 distributors/stockists’ network supported by a sales team of approximately 108 people. They primarily sell their products to distributors in India, who in turn supply to hospitals and nursing homes, etc.

  • The company’s entire manufacturing facility is located at a single location, and all of the company’s manufactured products are produced from Hariyala, district Kheda, Gujarat. Any delay in production at, or shutdown of, their manufacturing facility may in turn adversely affect their business, financial condition and results of operations.

  • They are significantly dependent on imports of plastic granules being primary packing material and are to that extent exposed to risks including duties placed on imports from other countries or regulatory or market concerns regarding materials sourced from such countries, fluctuations in global commodity prices, and foreign currency exchange fluctuations.

  • Reforms in the healthcare industry and the uncertainty associated with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for their products.

Particulars (in Rs. crores)

Parameter Amanta Healthcare Limited Denis Chem Lab Limited
Total Income for the year ended March 31, 2024 (₹ in crores)
281.6068
169.2097
P/E
-
18.76
EPS (Basic) (₹)
1.35
8.04
Return on Net Worth (%)
5.48
13.88
NAV per share (₹)
24.71
57.91

Anchor Investor Information

The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Issue Opening Date.

IPO Registrar and Book Running Lead Managers

Book running lead managers:

Beeline Capital Advisors Private Limited

Registrar for the IPO is MUFG Intime India Private Limited

Business Model

The company earns its revenue through the following sources:

  • Developing, manufacturing, and marketing a diverse range of sterile liquid products. Their product portfolio is categorised into six therapeutic segments: fluid therapy (IV fluids), formulations, diluents and injectables, ophthalmic solutions, respiratory care, and irrigation solutions.
  • Manufacture of products like irrigation, first-aid solution, eye lubricants etc. in medical device segment.
  • They also offer a wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume ranging from 2 ml to 1000 ml.

Company Growth Trajectory

The company has experienced growth in the past three years. Its total income has grown at a CAGR of 11.56% from ₹226.268 crores in fiscal 2022 to ₹281.607 crores in fiscal 2024. Its revenue from operations too has grown from ₹22,544.13 crores to 28,034.03 crores between FY22 to FY24.

Company Market Position

The company is positioned in the market as a well-established manufacturer of pharmaceutical formulations with a diverse product portfolio and diverse market with large manufacturing capabilities, wide domestic and international marketing network, and an experienced management team supported by a large, diverse, and skilled workforce.

As per the Draft Red Herring Prospectus, the company has 113 active product registrations with international authorities. Its diverse product portfolio gives it consistency and sustainability in business.

Parameter FY22 FY23 FY24
Total Revenue from operations (₹ crores)
225.4413
259.1293
280.3403
Profit Before Tax (₹ crores)
61.7873
2.6899
5.3889
Net profit / (loss) (₹ crores)
53.8817
2.1106
3.6332
EBITDA (₹ crores)
54.4558
56.3067
58.7565
EPS (₹)
20.08
0.79
1.35
Parameter FY22 FY23 FY24
Profit before tax (₹ crores)
61.7873
2.6899
5.3889
Net Cash from Operating Activities (₹ crores)
63.5341
42.5804
58.0730
Net Cash from Investing Activities (₹ crores)
5.3812
6.5319
10.3209
Net Cash from Financing Activities (₹ crores)
51.9868
42.3207
46.3238
Cash and Cash Equivalents (₹ crores)
6.3833
0.1111
1.5394

You can check the allotment status of shares either on the website of the Bombay Stock Exchange (BSE) or on the website of the registrar MUFG Intime India Private Limited. To check the status on the BSE website:

  • Visit the BSE website
  • Click on “Investor Services” and choose “Application Status Check”
  • Choose the issue type — Equity or Debt (Equity in this case)
  • Select the Issue Name from the drop-down. The issue name is the company’s name, which is Amanta Healthcare Limited
  • Enter your application number or PAN number
  • Check the box which says “I’m not a Robot” and click on “Search” to know the allotment status

Follow these steps to know the allotment status on the registrar’s website:

  • Visit the MUFG Intime India Private Limited website
  • Choose “Public Issues” from the “Investor Services” drop-down
  • Select Amanta Healthcare Limited from the drop-down
  • Enter your PAN number or Application number
  • Click on “Submit” to know the allotment status
Company NameBidding Dates
16 Jun - 18 Jun'25
16 Jun - 18 Jun'25
To be announced
18 Jun - 20 Jun'25
18 Jun - 20 Jun'25

Amanta Healthcare Ltd IPO FAQs

The Amanta Healthcare Limited IPO has an issue size of up to 1,25,00,000 equity shares. The IPO opens for subscription on TBA and closes on TBA.

You may read more about Amanta Healthcare Limited and its IPO from the company’s draft red herring prospectus (DRHP) here: (SEBI | Amanta Healthcare Limited - DRHP)

Company NameBidding Dates
16 Jun - 18 Jun'25
16 Jun - 18 Jun'25
To be announced
18 Jun - 20 Jun'25
18 Jun - 20 Jun'25
Open Demat Account to Invest in any IPO
+91 -

personImage
Open Demat Account to Invest in any IPO
+91 -